Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus.
Mutations of the p53 gene constitute one of the most frequent genetic alterations in squamous cell carcinoma of the head and neck (SCCHN). In this study, we introduced wild-type p53 into two separate SCCHN cell lines via a recombinant adenoviral vector, Ad5CMV-p53. Northern blotting showed that following infection by the wild-type p53 adenovirus (Ad5CMV-p53), cells produced up to 10-fold higher levels of exogenous p53 mRNA than cells treated with vector only (without p53). Western blotting showed that the increased levels of p53 protein produced in the Ad5CMV-p53-infected cells were a reflection of p53 mRNA expression. In vitro growth assays revealed growth arrest following Ad5CMV-p53 infection as well as cell morphological changes consistent with apoptosis. In vivo studies in nude mice with established s.c. squamous carcinoma nodules showed that tumor volumes were significantly reduced in mice that received peritumoral infiltration of Ad5CMV-p53. These data suggest that Ad5CMV-p53 may be further developed as a potential novel therapeutic agent for SCCHN since introduction of wild-type p53 into SCCHN cell lines attenuates their replication and tumor growth.
Department of Head and Neck Surgery, University of Texas M. D. Anderson Cancer Center, Houston 77030.
T J
TJ
Liu
W W
WW
Zhang
D L
DL
Taylor
J A
JA
Roth
H
H
Goepfert
G L
GL
Clayman
D000256:Adenoviridae / Q000235:genetics*; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D002455:Cell Division / Q000187:drug effects; D016158:Genes, p53; D015316:Genetic Therapy; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis / Q000494:pharmacology
D011994:Recombinant Proteins; D016159:Tumor Suppressor Protein p53